|
[1]Chagall, "Pharmaceutical Companies Returning to Taiwan to Form New Base," in Economic Daily News Taipei, 2006. [2]BMI, "Taiwan Pharmaceuticals and Healthcare Report Q2 2008," Business Monitor International, 2008. [3]E. Cox, A. Behm, and D. M. PharmD, "2005 Generic Drug Usage Report," 2004. [4]Indy, "2008我國產業生命力之新契機研討會 "學名藥之商機探索"." vol. 2008 Taipei: Taiwan Biotech Event Blog, 2008. [5]D. Pons, "Project management for new product development," Project Management Journal, vol. June, pp. 82-97, 2008. [6]ICH, "Quality Risk Management." vol. Quality Guide: International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2006. [7]C. Woolston, "Generic Drug Savings," CONSUMER HEALTH INTERACTIVE, 2003. [8]A. K. Basak, A. S. Raw, A. H. Al Hakim, S. Furness, N. I. Samaan, D. S. Gill, H. B. Patel, R. F. Powers, and L. Yu, "Pharmaceutical impurities: Regulatory perspective for Abbreviated New Drug Applications," Advanced Drug Delivery Reviews, vol. 59, pp. 64-72, 2007. [9]G. F. Meyer, "History and regulatory issues of generic drugs," Transplantation Proceedings, vol. 31, pp. 10S-12S, 1999. [10]R. P. Inc.(RPI), "Ranbaxy - Annual Report 2006," Ranbaxy Pharmaceuticals Inc.(RPI),2007. [11]J. Prasnikar and T. Skerlj, "New product development process and time-to-market in the generic pharmaceutical industry," Industrial Marketing Management, vol. 35, pp. 690-702, 2006. [12]W. Wong and B. Chatterjee, "Considerations in Effectively Applying Risk-Based Validation," Pharmatech Associates, Inc. , 2008, p. 2. [13]PMI, A Guide to the Project Management Body of Knowledge, Third ed.: Project Management Institute, 2004. [14]R. Mulcahy, PMP exam prep vol. 3th Edition: RMC Publications, 2005. [15]FDA, "Pharmaceutical cGMPs for the 21st Century: A Risk-Based Approach," Washington, DC,, 2002. [16]B. T. Barkley, Project Risk Management: McGraw-Hill Professional, 2004. [17]R. Mulcahy, PM Crash COURSE, Premier ed.: RMC Publications Inc., 2006. [18]G. Cassanelli, G. Mura, F. Fantini, M. Vanzi, and B. Plano, "Failure Analysis-assisted FMEA," Microelectronics and Reliability, vol. 46, pp. 1795-1799, 2006. [19]西村経営事務所, "FMEA手法 テキスト," 2004. [20]R. McDermott, R. Mikulak, and M. Beauregard, The Basics of FMEA: Quality Resources, 1996. [21]M. Swartz and I. Krull, "21 CFR Part 11 and Risk Assessment: Adapting Fundamental Methodologies to a Current Rule," LC-GC North America, vol. 25, pp. 48-55, 2007. [22]J. Yu and M. Kurwa, "Ensuring a Successful New Product Launch," in Circuits Assembly. vol. FEBRUARY: www.circuitsassembly, 2002. [23]R. L. Plackett and J. P. Burman, "The Design of Optimum Multifactorial Experiments," Biometrika, vol. 33, pp. 305-25, 1946. [24]NIST, "NIST/SEMATECH e-Handbook of Statistical Methods," NIST, 2006. [25]A. Vatanara, A. Rouholamini Najafabadi, K. Gilani, R. Asgharian, M. Darabi, and M. Rafiee-Tehrani, "A Plackett-Burman design for screening of the operation variables in the formation of salbutamol sulphate particles by supercritical antisolvent," The Journal of Supercritical Fluids, vol. 40, pp. 111-116, 2007. [26]B. Dejaegher, M. Dumarey, X. Capron, M. S. Bloomfield, and Y. Vander Heyden, "Comparison of Plackett-Burman and supersaturated designs in robustness testing," Analytica Chimica Acta, vol. 595, pp. 59-71, 2007. [27]K. Chauhan, U. Trivedi, and K. C. Patel, "Statistical screening of medium components by Plackett-Burman design for lactic acid production by Lactobacillus sp. KCP01 using date juice," Bioresource Technology, vol. 98, pp. 98-103, 2007. [28]D. L. Beres and D. M. Hawkins, "Plackett-Burman technique for sensitivity analysis of many-parametered models," Ecological Modelling, vol. 141, pp. 171-183, 2001. [29]D. G. WATSON, Pharmaceutical analysis: a textbook for pharmacy students and pharmaceutical chemists, SECOND ed.: Churchill Livingstone, 2005. [30]C. M. Douglas, Design and Analysis of Experiments, 6th ed., 2005. [31]Minitab User's Guide Release R13 for Windows: Minitab Inc., 2000. [32]"Q2(R1): Validation of Analytical Procedures: Text and Methodology," International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH), 2005. [33]"<1225> Validation of Compendial procedure," in United States Pharmacopoeia, 31th ed., National Formulary, 26th ed.,, 2008. [34]"<621> Chromatography," in United States Pharmacopoeia, 31th ed., National Formulary, 26th ed.,, 2008. [35]OGD, "Requesting Methods Validation for Abbreviated New Drug Applications (ANDAs)," C. F. D. E. A. RESEARCH, Ed., 1998. [36]ICH, "Q2 (R1) Validation of Analytical Procedures: Text and Methodology (CPMP/ICH/281/95)," International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), 2005. [37]<1225> Validation of Compendial Methods: United States Pharmacopoeia, 31th ed., National Formulary, 26th ed.,, 2008.
|